Primary in vitro sensitization of normal mouse spleen cells was accomplished using a saline soluble heterogeneous antigenic preparation from the whole adult worms (SWAP) of Schistosoma mansoni. A SWAP-specific rosette-forming cell (RFC) assay, using antigen on sheep erythrocytes, was used to detect sensitization due to S. mansoni infection and primary in vitro SWAP exposure. The latter exposure was facilitated by SWAP adsorption to the culture vessel via poly-L-lysine. RFC expression was maximal on day 3 of culture. It was antigen-specific in regard to unexposed controls, SWAP and human gamma globulin, and as controlled by RFC detected by parallel treated (control) erythrocytes. The RFC assay was best read between 90 and 180 min after initiation of rosette formation. Assay erythrocytes gave reproducible results for at least 3 weeks after preparation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0022-1759(82)90196-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Background: NEuroBioStand is an EU-funded project aimed at developing a metrological research framework for standardising blood-based biomarkers of neurodegenerative diseases (NDDs) with the objective of implementation and commercialisation of promising assays for NDD biomarkers fulfilling requirements of the in vitro diagnostic regulation (IVDR). P-tau is currently included in the AT(N) framework for AD diagnosis together with other biomarkers and amyloid-β and tau in CSF have been developed into regulatory approved biomarkers in CSF. The standardisation of the measurements for this biomarker is important to establish common cut-off values and reference ranges.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, and Memory Clinic, Skåne University Hospital, Malmö, Sweden.
Background: Alzheimer's disease (AD) is the leading cause of cognitive impairment and dementia with rising prevalence, morbidity, and mortality. Limited treatment options highlight a significant unmet need. AD is characterized pathologically by extracellular accumulation of Aβ peptide-containing plaques and intracellular neurofibrillary tangles containing aggregates of the microtubule-associated protein tau, leading to neuronal and synaptic loss, neuroinflammation, and brain atrophy.
View Article and Find Full Text PDFBackground: Antibody-drug conjugates (ADCs) represent a major advancement in oncology to deliver selectively cytotoxic drug to tumor cells while reducing their exposure to normal tissues. Each ADC consists of a monoclonal antibody (mAb) selective to a tumor specific/overexpressed surface antigen conjugated to the cytotoxic agent. In this study, we are investigating the potential of an ADC approach in neurodegenerative diseases (NDD) to increase the exposure of therapeutic mAbs in the brain using small molecules known to be brain penetrant.
View Article and Find Full Text PDFBackground: The accumulation of hyperphosphorylated, aggregated tau in neurons is one of the hallmarks of Alzheimer's disease (AD). Recent work in structural biology has solved the structure of tau fibrils in several tauopathies and found that the structure of the tau fibrils varies between diseases, but fibril structure is conserved among patients within the same disease, suggesting fibril structure relates to its pathogenicity. Tau fibrils derived from AD brain (AD PHFs) seed AD-like pathology in wild-type mice, yet efforts to recapitulate this seeding with recombinant fibrils have failed.
View Article and Find Full Text PDFBackground: Synaptic degeneration is characteristic of neurodegenerative diseases. Amyloid-beta (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated tau are known to induce the synapse pathologies directly or indirectly in Alzheimer's disease (AD). EphA4 is a member of the ephrin receptor subfamily which is predominantly expressed in the brain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!